Dublin, April 02, 2026 (GLOBE NEWSWIRE) — The “Tumor Models Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The tumor models market has been experiencing rapid growth, expanding from $2.13 billion in 2025 to an anticipated $2.37 billion in 2026, marking a compound annual growth rate (CAGR) of 11.3%. This growth is spurred by the scarcity of advanced tumor models, reliance on traditional 2D cell cultures, increasing cancer research funding, rising cancer prevalence, and the adoption of orthotopic and heterotopic models.
Looking forward, the market is expected to grow to $3.57 billion by 2030 at a CAGR of 10.8%. This anticipated surge is driven by advancements in organ-on-a-chip and 3D spheroid technologies, an intensified focus on personalized oncology treatments, the expansion of contract research organizations (CROs) in tumor research, increased pharmaceutical R&D expenditure, and the integration of AI and big data analytics in studies. Key trends include the increasing use of 3D tumor spheroids, organ-on-a-chip models, rising demand for personalized medicine, targeted cancer therapies, and growing collaboration between pharmaceutical firms and academic institutions.
The rising demand for personalized medicine is a significant growth factor for the tumor models market. Personalized medicine uses genetic information and lifestyle factors to tailor treatments, enhancing healthcare technology geared towards live monitoring and personalized therapy plans. Tumor models enable personalized medicine by simulating and predicting patient-specific tumor responses to treatments. For example, in 2024, the Personalized Medicine Coalition noted the FDA’s approval of 26 new personalized medicines, underscoring this trend’s influence on market expansion.
Leading companies in the market are advancing sophisticated tools like tumor spheroid models to enhance the realism and predictive power of lab-based cancer simulations. Predictive Oncology introduced state-of-the-art 3D cell technology in June 2024, aiming to accelerate cancer drug discovery. This technology includes advanced 3D tumor spheroid and organoid configurations, facilitating rapid screening and AI-driven analytics for improved therapy response predictions.
In October 2024, Merck & Co. Inc acquired Modifi Biosciences, a strategic move to bolster its oncology portfolio. Modifi Biosciences specializes in targeted small-molecule therapies for cancer cells with impaired DNA repair mechanisms, focusing on challenging cases like glioblastomas.
Major players in the tumor models market include WuXi AppTec Co Ltd., Charles River Laboratories International Inc., Pharmaron Beijing Co. Ltd., and others. In 2025, North America emerged as the largest market region, while Asia-Pacific is projected to be the fastest-growing region during the forecast period. The market is influenced by tariffs that have increased costs for imported laboratory equipment, leading to higher operational expenses and potential delays in research.
Reasons to Purchase:
- Acquire a global perspective with an extensive report covering 16 geographies.
- Evaluate the impact of macro factors like geopolitical conflicts, trade policies, inflation fluctuations, and evolving regulatory landscapes.
- Develop tailored regional and country strategies based on in-depth local data and insights.
- Identify promising growth segments for strategic investment.
- Utilize forecast data and market drivers to outperform competitors and understand end-user dynamics.
- Assess market potential and attractiveness using Total Addressable Market (TAM) and Market Attractiveness Scoring.
- Perfect for supporting internal and external presentations with high-quality data and insights.
- Receive timely updates and an Excel data sheet for easy data extraction and analysis.
Report Scope:
- Markets Covered: Primary, Metastatic, Orthotopic, and Heterotopic Tumor Models with applications ranging from Drug Discovery to Toxicology Studies. Technologies involved include Xenograft Models and 3D Tumor Spheroids.
- Countries and Regions: Coverage includes markets such as the USA, China, and Germany across regions like Asia-Pacific and North America.
- Data Insights: Provides ratios of market size to related markets, GDP proportions, and expenditure per capita, with detailed country and regional data segmentation.
- Delivery Format: Available in Word, PDF, or Interactive Report + Excel Dashboard.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $2.37 Billion |
| Forecasted Market Value (USD) by 2030 | $3.57 Billion |
| Compound Annual Growth Rate | 10.8% |
| Regions Covered | Global |
The companies featured in this Tumor Models market report include:
- WuXi AppTec Co. Ltd.
- Charles River Laboratories International Inc.
- Pharmaron Beijing Co. Ltd.
- The Jackson Laboratory
- Taconic Biosciences Inc.
- Cyagen Biosciences Inc.
- Crown Bioscience Inc.
- Champions Oncology Inc.
- InSphero AG
- Creative Biolabs Inc.
- Oncodesign S.A.
- Xentech S.A.
- MIMETAS BV
- Experimental Pharmacology and Oncology Berlin-Buch GmbH
For more information about this report visit https://www.researchandmarkets.com/r/j2r21o
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
